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over the follow-up period. After matching, there was no
signiﬁcant difference in health services utilization between
drug groups. However, risperidone subjects had signiﬁ-
cantly lower pharmacy costs (<.0001) and total costs (p
= 0.0181) compared to olanzapine subjects. Subjects with
affective disorders had total costs that were signiﬁcantly
higher compared to subjects with schizophrenia or child-
hood disorders. CONCLUSIONS: Studies comparing
cost and utilization among atypical antipsychotics should
consider the host of factors that may inﬂuence receipt or
regiment of care such as diagnostic condition, duration
of therapy and dosing.
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OBJECTIVE: Factors inﬂuencing atypical antipsychotic
selection include physician preference, and patient char-
acteristics. Studies comparing risperidone, quetiapine,
olanzapine and ziprasidone resulted in inconclusive evi-
dence suggesting superiority of one agent over another.
Amidst concerns over increasing drug expenditures, cost
has become a major issue in the drug sector. Therefore,
the purpose of this study is to model the potential annual
cost savings that may occur as a result of shifting utiliza-
tion from risperidone, quetiapine, and olanzapine to
ziprasidone within the Wisconsin Medicaid population.
METHODS: Retrospective review of Wisconsin Medic-
aid paid prescription claims data from January 1, 2001
to December 31, 2001. Utilization of schizophrenic doses
of risperidone, quetiapine, olanzapine, and ziprasidone
were extracted for this analysis. The main outcomes cal-
culated were cost per unit, mean cost per claim, and total
yearly expenditure per drug. To test the robustness of the
analysis, we modeled the total savings by estimating a
10%, 20% and 50% shift of risperidone, quetiapine and
olanzapine utilization to ziprasidone. RESULTS: Total
number of claims in 2001 for risperidone, quetiapine,
olanzapine and ziprasidone were 41,408, 36,722, 48,647,
and 9,288, respectively. The corresponding annual 
total dollar payouts were $8,705,264, $7,271,390,
$17,081,012, and $1,729,874 respectively. The cost per
claim for ziprasidone ($186.25) was signiﬁcantly lower
than olanzapine ($351.12), quetiapine ($198.01), and
risperidone ($210.23). A 50% shift to ziprasidone would
result in a total cost savings of $4,722,833,70 annually.
CONCLUSION: This analysis suggests that there is a
potential for substantial cost savings within the 
Wisconsin state Medicaid system that would occur as a
results of shifting utilization from other atypical antipsy-
chotics to ziprasidone.
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OBJECTIVES: The economic burden of depression was
estimated at approximately $44 billion in 1990. A sub-
sequent study reﬁned the estimation of the morbidity
costs associated with depressive disorders and revised this
ﬁgure to $53 billion. The objective of this study is 
to provide a 10-year update of the economic burden 
of depression using the same reﬁned methodology.
METHODS: Using a human capital approach we devel-
oped prevalence-based estimates of 3 major cost cate-
gories: 1) direct costs, 2) mortality costs arising from
depression-related suicides, and (3) morbidity costs 
associated with workplace depression. Estimates were
updated to reﬂect 2000 values, using the most current epi-
demiological data for prevalence rates and publicly avail-
able cost data by condition. RESULTS: We estimate that
the total economic burden of depression in 2000 was
$81.5 billion. Of this total, $26.1 billion—32%—are
direct medical costs, $5.4 billion—7%—are mortality
costs, and $49.9 billion—61%—are morbidity costs.
Work absenteeism resulted in $34.5 billion—42% of total
costs, while work cutback costs were $15.4 billion—19%
of total costs. CONCLUSIONS: The economic burden of
depression was $81.5 billion in 2000. Morbidity gener-
ated the largest portion, 61%, of these costs. Future
research investigations will incorporate additional costs
associated with depressive disorders, including the excess
costs of treating comorbid illnesses and the cost burden
of depressed individuals’ family members.
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OBJECTIVES: Depression is a major public health issue
in the United States. It is associated with high morbidity
and mortality. Hence it is important to evaluate its eco-
nomic impact on the U.S. health care system. Information
about the economic burden of depression will help 
in effective utilization and allocation of healthcare
resources. The main outcome measure of this study was
the economic burden of depression in a patient popula-
tion of 703 with a primary diagnosis of depression.
METHODS: A secondary database analysis was con-
ducted using the Medical Expenditure Panel Survey, 1999
(MEPS 99). Patients with primary diagnoses of depres-
sion were identiﬁed using International Classiﬁcation of
Diseases, 9th revision, Clinical Modiﬁcation (ICD 9 CM).
